|
2023 Conference Publication Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases RegistriesLim, Kenneth J. C., Wellard, Cameron, Moore, Elizabeth, Ninkovic, Slavisa, Chng, Wee-Joo, Spencer, Andrew, Mollee, Peter, Hocking, Jay, Ho, Phoebe Joy, Janowski, Wojt, Kim, Kihyun, Dun, Karen, McQuilten, Zoe K., Chen, Fiona and Quach, Hang (2023). Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-173896 |
|
2023 Conference Publication Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based RegimenChakravorty, Lipi, Gibbons, Anthea, Anderson, Nirija, Kwok, Fiona, Korczyk, Dariusz, Abro, Emad Uddin, Lam, Stephanie, Gibbs, Simon, Mollee, Peter and Sidiqi, M. Hasib (2023). Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-186335 |
|
2023 Conference Publication A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple MyelomaTang, Andy, Kim, Kihyun, Chen, Fiona, McQuilten, Zoe K., Mollee, Peter, Rajagopal, Rajeev, Quach, Hang, Ho, Phoebe Joy, Harrison, Simon J., Spencer, Andrew and Chng, Wee-Joo (2023). A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-178192 |
|
2023 Conference Publication High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLLSabdia, Muhammed B., Burgess, Melinda, Law, Soi Cheng, Thurgood, Lauren A., Kazakoff, Stephen, Swain, Fiona, Tobin, Joshua W.D., Mollee, Peter, Patch, Ann-Marie and Gandhi, Maher K (2023). High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-174149 |
|
2023 Conference Publication Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based ChemotherapyGibbons, Anthea, Ranjit Anderson, Nirija, Chakravorty, Lipi, Kwok, Fiona, Sidiqi, Hasib, Gibbs, Simon, Korczyk, Dariusz, Abro, Emad Uddin and Mollee, Peter (2023). Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-179219 |
|
2023 Conference Publication Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapyMollee, Peter, Gibbons, Anthea, Anderson, Niri Ranjit, Korczyk, Dariusz, Gibbs, Simon and Sidiqi, Hasib (2023). Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapy. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02056-6 |
|
2023 Conference Publication Localised light chain (AL) amyloidosis: presentation, treatment and outcomes; an observational studyAnderson, Nirija Ranjit, Abro, Emad, Korczyk, Dariusz and Mollee, Peter (2023). Localised light chain (AL) amyloidosis: presentation, treatment and outcomes; an observational study. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02060-8 |
|
2023 Conference Publication Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosisAnderson, Nirija Ranjit, Tobin, Joshua, Law, Phillip and Mollee, Peter (2023). Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosis. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02059-1 |
|
2023 Conference Publication More Efficient Delivery Of High-cost Standard-of-care Therapies In Relapsed Multiple Myeloma Using Real-time Feedback Of Patient-reported Outcome Measures: The My-prompt-2 TrialMoore, Elizabeth, Harrison, Simon, Ho, P. Joy, Irving, Adam, King, Tracy, Mccaughan, Georgia, Mcquilten, Zoe, Mollee, Peter, Park, Susanna, Petrie, Dennis, Reynolds, John, Rutherford, Claudia, van Tonder, Tina, Wellard, Cameron, Wood, Erica and Spencer, Andrew (2023). More Efficient Delivery Of High-cost Standard-of-care Therapies In Relapsed Multiple Myeloma Using Real-time Feedback Of Patient-reported Outcome Measures: The My-prompt-2 Trial. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000977464.68933.f0 |
|
2022 Conference Publication Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA TrialPerrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji K., Bahlis, Nizar Jacques, Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Pei, Huiling, Gupta, Niodita, Kaila, Shuchita, Matt, Kathryn, Gries, Katharine S., Carson, Robin, Borgsten, Fredrik and Weisel, Katja (2022). Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-165524 |
|
2022 Conference Publication A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)Roussel, Murielle, Mollee, Peter, Huart, Antoine, Sidiqi, Hasib, Horvath, Noemi, Karlin, Lionel, Jacquet, Caroline, Morel, Pierre, Leyronnas, Cecile, Bender, Sebastien, Bridoux, Frank, Jaccard, Arnaud and Gibbs, Simon D. (2022). A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP). 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166337 |
|
2022 Conference Publication An individualized exercise intervention improves quality of life for people with multiple myeloma: The MyeEx randomized waitlist-controlled trialNicol, Jennifer L., Hill, Michelle M., Cunningham, Brent, Woodrow, Carmel, Adlard, Kirsten, Mollee, Peter, Weber, Nicholas, Nicol, Andrew J. and Skinner, Tina L. (2022). An individualized exercise intervention improves quality of life for people with multiple myeloma: The MyeEx randomized waitlist-controlled trial. COSA's 49th Annual Scientific Meeting Equitable Cancer Care for All: Gender, Identity, Culture, Geography, and Disease Should Not Matter, Brisbane, QLD, Australia, 2–4 November 2022. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13868 |
|
2022 Conference Publication 76. “Gadgets and gizmos aplenty!” Dressing and securing peripherally inserted central catheters to prevent infection and failureRickard, Claire, Larsen, Emily, Marsh, Nicole, McGrail, Matthew, Ullman, Amanda, Kleidon, Tricia, Chan, Ray, Byrnes, Joshua, Mollee, Peter, Paterson, David, Chopra, Vineet, Stone, Leanne, Tapsall, Doreen, Keogh, Samantha, Gavin, Nicole, McCarthy, Sandie, Alexandrou, Evan, Choudhury, M.A., Corley, Amanda, Schults, Jessica, Ray-Barruel, Gillian and Geoffrey Playford, E. (2022). 76. “Gadgets and gizmos aplenty!” Dressing and securing peripherally inserted central catheters to prevent infection and failure. 2022 ACIPC International Conference, Sydney, NSW Australia, 13 - 16 November 2022. Amsterdam, Netherlands: Elsevier BV. doi: 10.1016/j.idh.2022.09.034 |
|
2022 Conference Publication Predictors of outcomes in patients with ATTRwt cardiac amyloidosisMew, T., Mollee, P. and Korczyk, D. (2022). Predictors of outcomes in patients with ATTRwt cardiac amyloidosis. 70th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Gold Coast, QLD Australia, 11-14 August 2022. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2022.06.115 |
|
2021 Conference Publication A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)Mollee, Peter, Reynolds, John, Janowski, Wojciech, Quach, Hang, Campbell, Philip, Gibbs, Simon D., Lee, Sophie, D'Rozario, James, Taylor, Kerry, Cochrane, Tara, Wallington-Beddoe, Craig Thomas, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian H., Weston, Helen, Ho, P. Joy, Horvath, Noemi, Yuen, Flora and Spencer, Andrew (2021). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-152500 |
|
2021 Conference Publication Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)Li Chai, Khai, Wellard, Cameron, Moore, Elizabeth M., Augustson, Bradley, Bapat, Akshay, Blacklock, Hilary Anne, Cooke, Rachel Elizabeth, Forsyth, Cecily, Hamad, Nada, Harrison, Simon J., Ho, Phobe Joy, Hocking, Jay, Kerridge, Ian H., King, Tracy, McCaughan, Georgia J., Mollee, Peter, Morrissey, Orla, Murphy, Nicholas E., Quach, Hand, Tan, Xuan Ni, Wong, Kimberly, Spencer, Andrew, Wood, Erica M. and McQuilten, Zoe (2021). Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-147622 |
|
2021 Conference Publication Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA StudyComenzo, Raymond, Palladini, Giovanni, Kastritis, Efsthathios, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Dispenzieri, Angela, Lee, Hans C., Sanchorawala, Vaishali, Gibbs, Simon D., Mollee, Peter, Venner, Chris P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Teresa Cibeira, M., Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Tran, Nam Phuong, Xin, Xiang, Khaled, Samer, Vermeulen, Jessica and Merlini, Giampaolo (2021). Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood-2021-146820 |
|
2021 Conference Publication A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, SealandQuach, Hang, Lasica, Masa, Routledge, David, Kalff, Anna, Lim, Andrew, Low, Michael, Estell, Jane A., Sidiqi, M. Hasib, Campbell, Philip, Eek, Richard Wilhelm, Lai, Hock C., McCaughan, Georgia J., D'Rozario, James, Browlett, Peter, Rajagopal, Rajeev, Heenan, Jessica, Murphy, Nicholas E., Renwick, William, Huan, Georgina and Mollee, Peter (2021). A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand. Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 04-08, 2021. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2021.39.15_suppl.TPS8055 |
|
2020 Conference Publication The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemiaMurali, Aarya, Cross, Donna and Mollee, Peter (2020). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemia. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. AMSTERDAM: American Society of Hematology. doi: 10.1182/blood-2020-140966 |
|
2020 Conference Publication Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from AndromedaComenzo, Raymond L., Kastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Sanchorawala, Vaishali, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Dimopoulos, Meletios A., NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y. ... Merlini, Giampaolo (2020). Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-137582 |
